Skip to content

Fetomaternal Alloimmune Thrombocytopenia 3 C6065895

Published: July 22, 2026Updated: August 20, 2026

Another form of maternal immune system attack on fetal platelets, similar to type 2, causing low platelet counts in the baby. It affects unborn and newborn babies. Treatment approaches include immunoglobulin therapy and transfusions.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Intracranial hemorrhage

!

Severe gastrointestinal bleeding

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Petechiae

(hematologic)

Epistaxis

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Maternal IVIG therapy

Intravenous immunoglobulin administered to the mother during pregnancy to reduce maternal antiplatelet antibodies and minimize fetal platelet destruction.

medication
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Corticosteroid therapy

Prenatal corticosteroids to suppress maternal antibody production and potentially improve fetal platelet counts when combined with IVIG.

medication

Additional treatment options

Intrauterine platelet transfusion

Direct fetal platelet transfusion under ultrasound guidance for severe thrombocytopenia. Provides temporary increase in fetal platelet count.

procedure

Intensive fetal surveillance

Regular ultrasound monitoring of fetal platelet counts, growth, and wellbeing throughout pregnancy to guide delivery timing and intervention decisions.

monitoring

Planned delivery with neonatal support

Coordinated delivery planning including caesarean section to minimize trauma risk and immediate neonatal hematology involvement for platelet transfusion if needed.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Fetomaternal Alloimmune Thrombocytopenia 3 C6065895?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Fetomaternal Alloimmune Thrombocytopenia 3 C6065895. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy